Literature DB >> 12851413

Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways.

Julie L Hanson1, Vasiliki Anest, Julie Reuther-Madrid, Albert S Baldwin.   

Abstract

Extensive data indicate that the transcription factor NF kappa B is activated by signals downstream of oncoproteins such as Ras or breakpoint cluster region (BCR)-ABL. Consistent with this, evidence has been presented that NF kappa B activity is required for Ras and BCR-ABL to transform cells. However, it remains unclear whether these oncoproteins activate a full spectrum of NF kappa B-dependent gene expression or whether they may augment or interfere with other stimuli that activate NF kappa B. The data presented here indicate that BCR-ABL expression in 32D myeloid cells or oncogenic Ras expression in murine fibroblasts blocks the ability of tumor necrosis factor (TNF) to activate NF kappa B. This suppression of NF kappa B is manifested by an inhibition of TNF-induced inhibitor of NF kappa B (IKK) activity and NF kappa B DNA binding potential but not by blocking TNF-induced nuclear accumulation of NF kappa B/p65. The inhibition of NF kappa B is not observed in oncogenic Raf-expressing cells and is not fully restored by the suppression of PI3-kinase or MEK pathways. Oncogenic Ras suppresses the ability of TNF to activate the expression of NF kappa B-dependent genes, such as iNOS (inducible nitric oxide synthase) and RANTES (regulated on activation normal T-cell expressed and secreted). These studies suggest that the ability of Ras and BCR-ABL to activate NF kappa B involves an uncharacterized pathway that does not involve classic IKK activity and that suppresses the TNF-induced IKK pathway through a Raf/MEK/Erk-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12851413     DOI: 10.1074/jbc.M304189200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein.

Authors:  Josephine H F Wixted; Jay L Rothstein; Laurence C Eisenlohr
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

2.  Small molecular weight G-protein, H-Ras, and retinal endothelial cell apoptosis in diabetes.

Authors:  Renu A Kowluru; Anjan Kowluru; Mamta Kanwar
Journal:  Mol Cell Biochem       Date:  2006-08-19       Impact factor: 3.396

3.  BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1.

Authors:  Aurore Keutgens; Xin Zhang; Kateryna Shostak; Isabelle Robert; Sabine Olivier; Alain Vanderplasschen; Jean-Paul Chapelle; Patrick Viatour; Marie-Paule Merville; Françoise Bex; André Gothot; Alain Chariot
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

4.  Chronic NF-kappaB activation delays RasV12-induced premature senescence of human fibroblasts by suppressing the DNA damage checkpoint response.

Authors:  Christina Batsi; Soultana Markopoulou; George Vartholomatos; Ioannis Georgiou; Panagiotis Kanavaros; Vassilis G Gorgoulis; Kenneth B Marcu; Evangelos Kolettas
Journal:  Mech Ageing Dev       Date:  2009-05-03       Impact factor: 5.432

Review 5.  Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy.

Authors:  Kirk E Cahill; Ramin A Morshed; Bakhtiar Yamini
Journal:  Neuro Oncol       Date:  2015-11-02       Impact factor: 12.300

6.  Aspirin inhibits epithelial-to-mesenchymal transition and migration of oncogenic K-ras-expressing non-small cell lung carcinoma cells by down-regulating E-cadherin repressor Slug.

Authors:  Poulami Khan; Argha Manna; Shilpi Saha; Suchismita Mohanty; Shravanti Mukherjee; Minakshi Mazumdar; Deblina Guha; Tanya Das
Journal:  BMC Cancer       Date:  2016-01-26       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.